ABT has successfully developed a breakthrough technology platform for brachytherapy. Unlike other brachytherapy technologies, ABT can attach a radionuclide to a bioabsorbable substrate, creating a multi-use, flexible delivery platform for radiation treatment. The preferred radionuclide is Palladium-103 but others may be used. Palladium-103 can also be attached to a non-resorbabale device surface.The nature of the nano-technology bonding the radioisotope with a device surface also allows for simultaneous deposition of chemotherapeutic drugs or other therapeutic products in combination with the radioisotope. The preferred bioabsorbabale substrate is traditional suture material commonly available.
The development of a bioabsorbabale brachytherapy delivery platform greatly enhances the number of cancer treatment applications for which brachytherapy can be considered. The ABT technology creates the opportunity for more localized and flexible tumor treatment for prostate, breast, head/neck, lung and other cancers. ABT technology is protected by several issued and pending patents.
To learn more about the ABT brachytherapy delivery platform click here.Also, please see our related-technology sister company, Radiation Decontamination Solutions, LLC at www.RadDecon.com.